Apretude

Understanding Apretude®

Apretude® (cabotegravir) is a long-acting injectable medication used for pre-exposure prophylaxis (PrEP) to prevent HIV infection in people at high risk. As the first and only injectable PrEP option, Apretude® offers a highly effective alternative to daily pills by providing sustained protection through periodic injections. This innovative treatment improves adherence, offers a discreet and convenient option, and is ideal for individuals who struggle with daily PrEP regimens and desire a low-maintenance HIV prevention strategy.

How Apretude® Works:

• Prevents HIV infection by blocking viral replication before exposure.
• Provides long-lasting protection with injections every two months.
• Eliminates the need for daily pills, enhancing adherence and convenience.

FDA Approval:

• Apretude® (cabotegravir): Approved in December 2021.

For more information, please visit the Apretude® patient website and speak with your healthcare provider to determine if Apretude® is the right prevention option for you.